“Bored already”, says Alistair Osborne in The Times. Equity markets were overjoyed when positive news of Pfizer’s Covid-19 vaccine trials broke earlier this month. But a similar update from AstraZeneca this week brought little more than a shrug. Global stockmarkets didn’t leap, but they have continued to trade close to recent highs. The MSCI World Index is up by 10% since the start of the month, with America’s S&P 500 up by 9%. The FTSE 100 has been a standout performer, gaining 15% in November, although British blue chips are still down by 15% for the year to date. Bulls have gone rampaging through bitcoin and oil markets.
Caught between Covid-19 and a cure
Never mind the market reaction, says Craig Erlam of OANDA Europe. The AstraZeneca vaccine is easier to store than its peers and is much cheaper. Investors must remember that vaccine makers are not in competition with each other. Constrained supply means that “the more successes we have the faster the global economy can get back on its feet… the light at the end of the tunnel is shining a little brighter.”
“It is the best of times and the worst of times, as Charles Dickens wrote”, says Randall Forsyth in Barron’s. “Optimism reigns” in markets as traders look forward to a strong rebound next year. A Bank of America survey reports that money managers have upped their stock allocations to the highest levels since January 2018. Yet back in the present a sagging recovery and new Covid-19 restrictions mean the current picture remains miserable. A vaccine next year is not very helpful if you get infected today, as John Authers points out on Bloomberg. The autumn virus wave is now very much in evidence in the US. New York City closed schools last week; the move hit “close to home” for many traders and triggered a pullback on Wall Street. Daily deaths are already at a six-month high and new infections continue to surge. “One last horrible dose of the virus” awaits us before this “dark winter” is over.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The bulls prepare
US equity markets do look “a bit exhausted” after this year’s exertions, says Michael Wilson of Morgan Stanley. There is a decent chance of “one more drawdown” before the end of the 2020. Nevertheless, the outlook for 2021 is unambiguously bullish. The vaccines will bring a new multi-year economic cycle, which almost always powers stocks higher. “We forecast 10% upside over the next 12 months” for the S&P 500.
Not so fast, says Michael Mackenzie in the Financial Times. Investors who got in early during past economic cycles were buying in markets offering heavily discounted valuations. Yet US valuations are already historically high, effectively meaning that much of the future recovery is already priced in. That also goes for cyclical stocks: it usually takes four or five years for US small-cap and industrial share prices to make new highs after recessions, says Nicholas Colas of DataTrek. Yet both sub-indexes are already trading above their previous all-time highs in America and the economic recovery hasn’t even started yet.
-
Review: Stank House Farm – a cosy cottage in YorkshireTravel Stank House Farm is a charming holiday cottage in North Yorkshire, close to Bolton Abbey and several wonderful walks
-
The battle of the bond markets and public financesAn obsessive focus on short-term fiscal prudence is likely to create even greater risks in a few years, says Cris Sholto Heaton
-
The battle of the bond markets and public finances
An obsessive focus on short-term fiscal prudence is likely to create even greater risks in a few years, says Cris Sholto Heaton
-
STS Global Income & Growth: Buying quality at a discountInvestors should consider STS Global Income & Growth to diversify away from mega-cap tech
-
'We still live in Alan Greenspan’s shadow'When MoneyWeek launched 25 years ago, Alan Greenspan was chairman of the Federal Reserve. We’re still living with the consequences of the whirlwind he sowed
-
Venture capital trusts that offer growth, income and tax reliefOpinion Alex Davies, founder of high-net-worth investment service Wealth Club, picks three venture capital trusts where he'd put his money
-
Go for growth: how to invest in emerging marketsDeveloping countries offer investors compelling long-term economic prospects, says David Prosser
-
How to invest in private equityNew forms of private equity funds give access to ordinary investors of more modest means. Should they rush in?
-
Isaac Newton's golden legacy – how the English polymath created the gold standard by accidentIsaac Newton brought about a new global economic era by accident, says Dominic Frisby
-
Investing in AI – the ultimate bubbleIs it “different this time”, or are we in the mother of all bubbles? The economics of AI should give investors pause for thought, says Dan McEvoy
